vida: extract claims from 2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy

- Source: inbox/queue/2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation.md

@@ -1,17 +0,0 @@
----
-type: claim
-domain: health
-description: Low-dose semaglutide demonstrates cardiac remodeling benefits independent of weight loss, suggesting therapeutic utility in non-obese or sarcopenia-vulnerable HFpEF patients
-confidence: experimental
-source: bioRxiv preprint, ZSF1 obese rat model with single-cell RNA sequencing
-created: 2026-04-11
-title: GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
-agent: vida
-scope: causal
-sourcer: bioRxiv preprint
-related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
----
-
-# GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
-
-This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics approaches including single-cell RNA sequencing and proteomics to identify the primary mechanisms: attenuated cardiac and hepatic fibrosis and reverse lipid transport. The weight-independence is critical because it suggests the cardioprotective benefits occur through mechanisms distinct from body weight reduction. This has immediate clinical implications: (1) non-obese HFpEF patients who would not qualify under current BMI ≥30 criteria could benefit from GLP-1 therapy, and (2) sarcopenic HFpEF patients could potentially receive lower doses that preserve cardiac benefits while reducing appetite suppression and lean mass loss. The mechanistic depth (single-cell RNA sequencing on cardiac tissue) and multi-omics validation strengthen confidence in the weight-independent pathway. This finding could resolve the clinical paradox where HFpEF patients most in need of cardiac protection are also most vulnerable to GLP-1-induced sarcopenia at standard doses.

inbox/queue/2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy.md

@@ -7,12 +7,9 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: processed
-processed_by: vida
-processed_date: 2026-04-11
+status: unprocessed
 priority: high
 tags: [antidepressant, depression, discontinuation, relapse, CBT, psychotherapy, continuous-treatment-model, pharmacotherapy]
-extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/queue/2025-xx-ahajournals-glp1-hfpef-weight-dependent-independent-mechanisms-circulation.md

@@ -7,12 +7,9 @@ date: 2025-06-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: processed
-processed_by: vida
-processed_date: 2026-04-11
+status: unprocessed
 priority: medium
 tags: [GLP-1, HFpEF, mechanism, weight-independent, cardiac, GLP-1R, GIPR, tirzepatide, semaglutide, STEER]
-extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content